Valuation: Alector, Inc.

Market Cap 28Cr 25Cr 23Cr 21Cr 39Cr 2.62TCr 39Cr 274.24Cr 107.61Cr 1.38TCr 104Cr 101.84Cr 4.38TCr P/E 2026 *
-4.14x
P/E 2027 * -2.24x
Enterprise Value 1.52Cr 1.36Cr 1.26Cr 1.14Cr 2.14Cr 143.75Cr 2.17Cr 15Cr 5.91Cr 76Cr 5.71Cr 5.6Cr 240.78Cr EV / Sales 2026 *
0.23x
EV / Sales 2027 * -2.51x
Free-Float
92.61%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Alector, Inc.

1 day-1.87%
1 week-2.58%
Current month+0.58%
1 month-7.42%
3 months+21.62%
6 months-24.05%
Current year+19.28%
1 week 1.76
Extreme 1.765
2.18
1 month 1.73
Extreme 1.73
2.73
Current year 1.37
Extreme 1.37
2.76
1 year 1.09
Extreme 1.09
2.76
3 years 0.87
Extreme 0.87
8.9
5 years 0.87
Extreme 0.87
27
10 years 0.87
Extreme 0.87
43.32
Manager TitleAgeSince
Chief Executive Officer 71 01/05/2013
Director of Finance/CFO 52 20/06/2025
Chief Tech/Sci/R&D Officer - 01/01/2017
Director TitleAgeSince
Director/Board Member 71 01/05/2013
Director/Board Member 72 01/10/2018
Chairman 77 13/06/2023
Date Insider Type Main position Quantity % Market Cap. Importance
14/10/26 Free

Controller/Auditor

1,38,990 0.1245%
14/10/26 Free

Founder

11,96,250 1.0714%
14/10/26 Free

Chief Financial Officer

2,34,567 0.2101%
Change 5-day change 1-year change 3-year change Capi.($)
-1.87%-2.58%+15.58%-63.87% 28Cr
-0.21%-4.43%+44.40%+74.13% 6.62TCr
+1.55%+5.30%+12.63%+77.16% 5.52TCr
+1.28%+4.74%+12.93%+93.04% 5.28TCr
+0.44%+2.50%+27.52%+51.22% 4.55TCr
-1.07%+2.36%+22.12%+126.93% 4.39TCr
-1.61%+2.25%+265.25%+954.26% 4.16TCr
+0.10%+9.90%+16.11%+59.33% 3.4TCr
-8.38%-6.95%+26.35%-1.93% 2.58TCr
+1.37%+4.90%+38.18%+27.98% 2.35TCr
Average -0.84%+3.61%+48.11%+139.83% 3.89TCr
Weighted average by Cap. -0.35%+3.72%+50.70%+165.40%

Financials

2026 *2027 *
Net sales 6.62Cr 5.89Cr 5.46Cr 4.94Cr 9.3Cr 624.24Cr 9.42Cr 65Cr 26Cr 328.12Cr 25Cr 24Cr 1.05TCr 1.14Cr 1.02Cr 94.03L 85.09L 1.6Cr 107.55Cr 1.62Cr 11Cr 4.42Cr 57Cr 4.28Cr 4.19Cr 180.14Cr
Net income -5.1Cr -4.55Cr -4.21Cr -3.81Cr -7.18Cr -481.58Cr -7.26Cr -50Cr -20Cr -253.14Cr -19Cr -19Cr -806.63Cr -11Cr -9.88Cr -9.14Cr -8.27Cr -16Cr -1.05TCr -16Cr -109.62Cr -43Cr -549.7Cr -42Cr -41Cr -1.75TCr
Net Debt -26Cr -23Cr -22Cr -20Cr -37Cr -2.47TCr -37Cr -259.17Cr -101.69Cr -1.3TCr -98Cr -96Cr -4.14TCr -31Cr -27Cr -25Cr -23Cr -43Cr -2.89TCr -44Cr -302.51Cr -118.7Cr -1.52TCr -114.73Cr -112.34Cr -4.83TCr
Projected Income Statement - Annual - Alector, Inc.
Logo Alector, Inc.
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
Employees
103
Date Price Change Volume
22/26/22 $1.802 -3.64% 2,73,994
21/26/21 $1.870 -5.08% 11,41,620
20/26/20 $1.970 +1.03% 20,21,359
19/26/19 $1.950 +5.98% 23,67,825
16/26/16 $1.840 -3.66% 51,57,884
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Alector, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
1.870USD
Average target price
3.900USD
Spread / Average Target
+108.56%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Alector, Inc.
  1. Stock Market
  2. Stocks
  3. ALEC Stock